3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
4
Status
Completed
4
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Classical hematology
4
Conditions
Carcinoma, Non-Small-Cell Lung
32
Breast Neoplasms
25
Parkinson Disease 4, Autosomal Dominant Lewy Body
19
Multiple Myeloma
13
Neoplasms
12
Leukemia, Myeloid, Acute
12
Ovarian Neoplasms
10
Neoplasm Metastasis
10
Leukemia, Lymphocytic, Chronic, B-Cell
10
Carcinoma, Renal Cell
10
Prostatic Neoplasms
8
Colorectal Neoplasms
8
Melanoma
7
Lymphoma, Non-Hodgkin
7
Leukemia
7
Stomach Neoplasms
6
Recurrence
6
Fallopian Tube Neoplasms
6
Carcinoma, Hepatocellular
6
Carcinoma
6
Urinary Bladder Neoplasms
5
Small Cell Lung Carcinoma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma
5
Adenocarcinoma
5
Purpura, Thrombocytopenic, Idiopathic
4
Myelodysplastic Syndromes
4
Lymphoma, Follicular
4
Liver Neoplasms
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Interventions
emicizumab
4
recombinant FVIIa
1
anti-inhibitor coagulant complex
1
Factor VIII
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Phase 3
×
Has announcements
×
Hemophilia A
×
Clear all
NCT03020160
2023-01-11
HAVEN 4
Hoffmann-La Roche
Phase 3
Completed
48 enrolled
44 charts
1 FDA
NCT02847637
2022-11-16
HAVEN 3
Hoffmann-La Roche
Phase 3
Completed
152 enrolled
46 charts
1 FDA
NCT02622321
2021-06-24
HAVEN 1
Hoffmann-La Roche
Phase 3
Completed
113 enrolled
45 charts
1 FDA
NCT02795767
2021-06-02
HAVEN 2
Hoffmann-La Roche
Phase 3
Completed
88 enrolled
65 charts
1 FDA